Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in h

New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diag

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform SALT LAKE CITY, Oct.

Halozyme Therapeutics (NASDAQ: HALO - Get Free Report) and Co-Diagnostics (NASDAQ: CODX - Get Free R

Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Re

Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and te

SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30

In August 2026, Co-Diagnostics, Inc. (the "Company") entered into a material transfer agreem

Two full laboratory installations completed in Florida; installation and customer training underway

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Predict

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s

On September 2, 2026, Co-Diagnostics, Inc. (the "Company") and Brian Brown, the Company’s Ch

Localized cloud environment is designed to support ongoing clinical studies and establish the digita

Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base repre

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stake

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

On Thursday, Co-Diagnostics (NASDAQ:CODX) discussed second-quarter financial results during its earn

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(1.46) per share which beat the analyst cons

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expan

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro

Merck and Wellcome-backed Hilleman will manufacture Bundibugyo Ebola vaccine doses for clinical tria

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the C

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ®

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evalu

Forte Biosciences shares rose 38.9% to $76.10 in pre-market trading after argenx SE announced plans

PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July

Co-Diagnostics' India joint venture CoSara has started clinical studies for its rapid TB PCR tes

Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plan

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

https://www.cdc.gov/ebola/situation-summary/index.html